The dispute matters because “enforcement priorities” can shape what remains on shelves and online while FDA reviews applications. FDA says its guidance is not authorization—it’s about how it intends to allocate enforcement resources in limited circumstances.

What FDA issued in May 2026

In guidance dated May 8, 2026, FDA described enforcement priorities for certain new tobacco products marketed without premarket authorization. FDA says the document does not create legally enforceable obligations and is nonbinding.

FDA also says it will create and maintain a publicly available list identifying manufacturers and products that fall within the categories where FDA says it generally does not intend to prioritize enforcement.

Under the policy, FDA says it generally does not intend to prioritize enforcement of the premarket authorization requirement where a covered product has a pending application that has been accepted and filed, or where a supplemental PMTA (sPMTA) has been accepted and is pending for more than 180 days. For certain non-tobacco-flavored ENDS products, FDA also adds an additional condition tied to whether FDA has determined the application includes data needed for evaluation under the public health standard.

FDA adds guardrails: the agency says it does not intend to apply the non-prioritization approach if the product has “presumptively underage-appealing” elements (such as depicting a cartoon-like fictional character, disguising it as a vaping product, or resembling a children’s toy, phone, or gaming platform) or if FDA determines the product presents a significant public health or safety concern—examples include high nicotine content, serious adverse experiences, lack of child-resistant packaging, or potential fire hazard.

Importantly for readers: FDA says a product’s inclusion in these enforcement categories has no bearing on whether the tobacco product will receive premarket authorization.

The lawsuit: what challengers say the policy does

The case was filed in the U.S. District Court for the District of Maryland (case number 8:2026cv02767). The docket listing shows plaintiffs including the Campaign for Tobacco-Free Kids, the American Academy of Pediatrics, the American Cancer Society Cancer Action Network, the American Heart Association, the American Lung Association, Parents Against Vaping e-Cigarettes, Truth Initiative, and individual plaintiffs.

According to the plaintiffs’ allegations as described in coverage and their public-facing explanations, the challenge argues FDA’s guidance unlawfully allows unauthorized products to be marketed without the scientific review and prior authorization required by federal law. The lawsuit also alleges the agency should have followed public notice-and-comment requirements and that FDA acted “arbitrary and capricious” by creating what plaintiffs describe as an “enforcement safe harbor.”

This filing is not a court decision on the merits—it starts the process where both sides can argue what the guidance means legally and what remedy, if any, a judge should order.

What to watch next

The next developments are procedural but potentially consequential. Watch the court docket for any requests for emergency relief that could change FDA’s enforcement posture for products covered by the guidance. On the agency side, keep an eye on whether FDA revises, clarifies, or further implements the May 2026 policy—especially around how it operationalizes the promised public list.

Sources

• FDA Center for Tobacco Products (CTP) newsroom: May 8, 2026 guidance overview
• U.S. District Court docket (District of Maryland) via Justia: Campaign For Tobacco-Free Kids et al v. FDA (8:2026cv02767)
• Truth Initiative press release: lawsuit summary and plaintiff list (July 14, 2026 coverage)
• Bloomberg Law (July 14, 2026): reporting on the FDA enforcement-policy lawsuit

What changed in FDA’s May 8 guidance

FDA’s guidance, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization,” lays out when the agency says it does not intend to prioritize enforcement against some unauthorized electronic nicotine delivery systems (ENDS, often described as “vapes”) and oral nicotine pouch products.

According to FDA, the “does not intend to prioritize” posture applies when, for the relevant product category, the manufacturer has a pending application that has been accepted and filed—or has a pending and accepted Supplemental PMTA—and FDA has determined the application includes data needed to evaluate whether the product is appropriate for protecting public health for non-tobacco flavored ENDS.

FDA also says that even for products that fall within those categories, it does not intend to prioritize enforcement where the product includes certain presumptively underage-appealing elements—such as depicting a cartoon-like fictional character, disguising the product’s nature as a vaping product, or resembling a children’s toy, phone, or gaming platform.

To promote transparency, FDA says it will create and maintain a public list of products identifying manufacturers and products that FDA does not intend to prioritize for enforcement under this policy.

Just as important: FDA’s guidance page says FDA guidances do not establish legally enforceable responsibilities; they reflect the agency’s current thinking and are recommendations unless specific regulatory or statutory requirements are cited.

Why plaintiffs say the policy is unlawful

The complaint (Case No. 8:26-cv-02767-ABA) names FDA and the U.S. Department of Health and Human Services as defendants, along with Acting Commissioner Kyle Diamantas (in his official capacity) and HHS Secretary Robert F. Kennedy, Jr. (in his official capacity).

The plaintiffs argue the May 8 guidance creates an enforcement “safe harbor” effect—allowing potentially thousands of unauthorized ENDS and nicotine pouch products to enter and remain on the market for an indefinite period while premarket reviews are underway—despite the Tobacco Control Act’s requirement that new tobacco products receive an FDA marketing granted order before entering the market. The complaint also alleges the guidance is unlawful under the Administrative Procedure Act framework.

What relief the plaintiffs are asking for

Plaintiffs are seeking declaratory and injunctive relief. Practically, they are asking the court to block the guidance’s use—potentially including vacating it—so FDA cannot rely on the policy to keep some unauthorized products in a lower-priority enforcement posture while PMTA reviews continue.

What to watch next

Next steps in court will likely focus on whether the case proceeds on an expedited schedule and whether the plaintiffs can obtain immediate relief (such as a temporary restraining order or preliminary injunction). If the court blocks or narrows the guidance, the biggest reader-facing change would be whether—and how quickly—FDA shifts from a “do not prioritize enforcement” approach to taking enforcement actions against categories of products covered by the policy.

Sources

• Court complaint (primary record)
• FDA guidance landing page (disclaimer + metadata)